Clinical Trials

Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or Patricia.Gambino@uphs.upenn.edu to make an appointment with one of our Oncologists to discuss clinical trials. 

Adjuvant
Trial # Trial Type of therapy Description PI/Contact
UPCC 04218 Immunotherapy Adjuvant Pilot study of mature dendritic cell vaccination against mutated KRAS in patients with resectable pancreatic cancer (KRAS dendritic cell vaccine with cyclophosphamide lymphodepletion) Adham Bear/Mark O'Hara
EA2192 (APOLLO) Olaparib Adjuvant Randomized, double blind study of olaparib vs placebo following adjuvant platinum based chemotherapy in patients with respectable pancreatic adenocarcinoma and a pathogenic BRCA1, BRCA2 or PALB2 mutation

Mary Oladjei/Kim Reiss

UPCC 24922 (Elicio)

Immunotherapy Adjuvant First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and other solid tumors (P: ELI-002 7P - a therapeutic vaccine

Mark O'Hara/Christina Haas/Vijay Kumar

 

Neoadjuvant
Trial # Trial Type of therapy Description PI/Contact

UPCC 24223 (Columbia U)

Immunotherapy, radiation therapy, surgical resection Neoadjuvant A Phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection. (Drugs: Zimberelimab (AB122; anti-PD-1), Quemliclustat (AB680 anti-CD73), Etrumadenant (AB298; A2a/A2b inhibitor) Mark O'Hara/Alyssa Donze/Asal Kareem

 

Localized, Resectable
Trial # Trial Type of therapy Description PI/Contact

 

Localized, Unresectable

Trial # Trial Type of therapy Description PI/Contact
UPCC 32213 Radiation & nab®-Paclitaxel Locally advanced A phase I dual dose escalation study of radiation and nab-paclitaxel in patients with unresectable and borderline resectable pancreatic cancer Taylor Siegal/Edgar Ben-Josef

 

Metastatic trials — First Line (Initial treatment for newly metastatic diagnosis)
Trial # Trial Type of therapy Description PI/Contact

UPCC 07220 (ARCUS)

AB680 (CD73 inhibitor) 1st line metastatic Phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies (gem/abraxane, AB680 (CD73 inhibitor that decreases adenosine) Mark O'Hara/Natalia Izgur/Carla Wright
UPCC 23222 Gemcitabine, nab-paclitaxel, defactinib 1st line metastatic Phase lb/2a study of gemcitabine and nab-paclitaxel in combination with BS-6766 and defactinib in patients with previously untreated metastatic adenocarcinoma Christina Haas/Mark O'Hara

 

Metastatic Trials — Second Line
Trial # Trial Type of therapy Description PI/Contact
UPCC 03821 Modified human CAR T cells 2nd line - Metastatic Pancreatic Cancer Phase I study of human CAR modified T cells (huCART-meso) administered in combination with VCN-01 (hyaluronidase-secreting oncolytic adenovirus) in PDAC and ovarian cancers. ECOG 0 patients preferred Kim Shea/Mark O'Hara
UPCC 18223 Gemcitabine, GP-2250 (metabolic inhibitor) 2nd line metastatic A Phase 1 trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GP-2250 in combination with gemcitabine in subjects with advanced unresectable or metastatic pancreatic adenocarcinoma who have progressed on prior treatment with 5-fluorouacil-based chemotherapy Jennifer Kandle/Mark O'Hara

 

Metastatic Maintenance
Trial # Trial Type of therapy Description PI/Contact

SIV S2001

PARP inhibitor 1st line - Maintenance Metastatic A randomized Phase II clinical trial of Olaparib + Pembrolizumab vs. Olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with Germline BRCA1 or BRCA2 mutations Kim Reiss

 

Biomarker Trials
Trial # Trial Type of therapy Description PI/Contact
  Pancreatic tissue acquisition No therapy Protocol to permit the acquisition of samples of tumor and normal tissue for biological endpoints in pancreatic cancer Kim Reiss/Ben Stanger
UPCC 02215 Circulating tumor material No therapy Protocol to permit the acquisition of circulating tumor material in pancreatic diseases and control subjects Peter O'Dwyer
UPCC 20222 Blood sample No therapy Protocol to permit collection of circulating biomarkers in pancreatic cancer Vijay Kumar/Mark O'Hara

 

Please contact your Abramson Cancer Center Oncologist about enrollment into a trial. If you do not have an Abramson Cancer Center Oncologist, please contact our Pancreas Nurse Navigator Patricia Gambino at 215-615-0537 or patricia.gambino@uphs.upenn.edu to make an appointment with one to discuss clinical trials.

Please note that openings for clinical trials are highly variable. Consequently, at any given time there may not be open slots for the trials shown here. Conversely, slots may be available for clinical trials that have not yet been listed on this page. To determine whether a clinical trial may be appropriate for you, please contact your Abramson Cancer Center Oncologist at 1-800-789-7366.